ArticleESMO real world data and digital oncology2026
Adolescents and young adults with cancers: comparative analyses of incidence and survival between Europe and the United States.
Article in ESMO real world data and digital oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Epidemiological data on cancers in adolescents and young adults (AYAs; aged 15-39 years) suggest rising incidence of AYA cancers alongside international differences in incidence and survival. We compared incidence, survival and trends over time for cancers in AYAs in the European Union (EU) and the United States. Materials and methods: We used the EUROCARE-6 database and the US SEER program. We calculated crude incidence rates (IRs) over the years 2006-2013. We calculated 5-year relative survival (RS) in the follow-up period 2010-2014 using the period approach based on cases diagnosed in 2006-2013. We analysed IR and RS changes for the years 2000-2013. Results: Overall, 5-year RS was ∼84% in the EU and United States and improved over time in both regions. Compared with US patients, AYA cancer patients in the EU had lower survival for central nervous system (CNS) tumours and malignant melanoma but higher survival for leukaemias, testicular germ cell tumours (TGCTs), and cervical cancer. Both in the EU and the United States, major improvements in 5-year RS were observed for leukaemias, CNS tumours, lymphomas, and breast cancers. Cancer in AYAs corresponds to ∼5% of all new cancers diagnosed in the EU and United States. The IR increased for all cancers in AYAs in both regions, with the biggest increase due to thyroid cancers, TGCTs, and colorectal cancer. Conclusions: Our results show survival improvements for most types of AYA cancers and underline the need for further international efforts to increase survival for tumours (e.g. CNS tumours) for which 5-year RS remains <60%. Furthermore, the increasing incidence underscores the importance of giving priority to cancer prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.